查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046147

直接抗病毒藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、適應症、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Direct-acting Antiviral Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Indication, By Route, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球直接作用抗病毒藥物市場預計將從 2025 年的 119.1 億美元大幅成長至 2031 年的 237.1 億美元，複合年成長率高達 12.16%。

直接抗病毒藥物（DAAs）是專門針對病毒複製週期中特定非結構蛋白的藥物，能夠有效抑制病毒複製，並對丙型肝炎等感染疾病實現較高的治癒率。該市場的成長主要受全球慢性病毒性疾病盛行率上升以及世界衛生組織為實現疾病根除目標而進行的協調努力的推動，而這些目標需要廣泛採用有效的治療方法。例如，美國肝病研究協會（AASLD）估計，到2025年，全球將有約5,000萬人患有C型肝炎，凸顯了對這類治療方法的巨大需求。儘管臨床需求龐大，但品牌療法的高成本限制了患者的取得，市場面臨許多挑戰，尤其是在資源匱乏的地區。這種經濟障礙常常迫使醫療系統實施嚴格的報銷標準或醫療發行配給，從而阻礙了這些治療方法的廣泛應用，並限制了中低收入國家（這些國家往往是此類疾病負擔最重的國家）的整體市場潛力。

市場概覽
預測期 2027-2031
市場規模：2025年 119.1億美元
市場規模：2031年 237.1億美元
複合年成長率：2026-2031年 12.16%
成長最快的細分市場 NS3/4A蛋白酶
最大的市場 北美洲

市場促進因素

丙型肝炎和愛滋病毒感染在全球範圍內的持續蔓延是全球直接抗病毒藥物市場的主要驅動力，確保了對治療性介入的持續需求。隨著病毒感染率的不斷攀升，醫療衛生系統越來越需要實施先進的抗病毒療法，以有效控制疾病負擔並防止病情發展至慢性期。這種需求與需要立即接受治療和持續病毒抑制的新病例數量直接相關。根據聯合國愛滋病規劃署（UNAIDS）於2024年7月發布的《全球愛滋病統計概況》，預計2024年全球將新增約130萬愛滋病毒感染者。這意味著患者數量的持續成長刺激了市場擴張，因為製造商正在擴大生產規模以滿足不斷成長的人口的需求，尤其是在那些將有效病毒抑製作為首要任務的地區。此外，強大的臨床研發管線和持續的研發投入也進一步推動了市場成長，這些都有助於開發長效、高效的療法。製藥公司正積極研發新一代直接抗病毒藥物，以期獲得更優的臨床療效、減少給藥頻率並顯著提高病患依從性。近期愛滋病預防領域的臨床突破便是這項創新的顯著例證。 2024年9月，吉利德科學公司報告稱，其在研的每年兩次注射的lenacapavir在PURPOSE 2試驗中，與基準感染率相比，HIV感染率降低了96%，展現了這一新型療法的巨大潛力。這種對提升療效的重視，正直接轉化為主要市場參與者的強勁商業性成功。吉利德科學公司2024年第三季HIV相關產品的銷售額成長9%，達到51億美元，這充分反映了臨床需求向營收的有效轉換。

市場挑戰

品牌療法的高昂價格是阻礙全球直接抗病毒藥物市場成長的一大經濟障礙。在許多地區，尤其是在疾病負擔最為集中的中低收入國家，國家醫療預算往往不足以支撐這些取得專利的治療方法的高價。這種經濟壓力迫使公共醫療系統實施嚴格的藥物發行方案，通常只允許晚期肝損傷患者獲得藥物，從而延誤了更多感染者的治療。結果，市場規模被人為抑制，導致高臨床盛行率無法轉化為實際的藥物銷售。這種可負擔性方面的差距造成了高效治療方法存在與其廣泛應用之間的巨大鴻溝。當價格過高，對當地經濟造成負擔，且醫療基礎設施無法支持大規模採購時，市場擴張就會受到抑制。根據2024年世界肝炎聯盟的數據，全球僅有15%的C型肝炎確診患者接受了必要的治療，凸顯了這些獲取障礙的嚴重影響。這些限制使得目標市場的大部分未能開發，阻礙了該行業充分發揮其全球收入潛力。

市場趨勢

一個值得關注的策略趨勢是追求乙型肝炎的功能性治愈，將重點從終身病毒抑制轉向短期治療。這一趨勢正在推動創新反義寡核苷酸的研發，這些藥物旨在去除病毒表面抗原，從而滿足以維持治療為主導的治療環境中尚未得到充分滿足的需求。近期臨床進展也支持此方向。例如，葛蘭素史克（GSK）於2026年1月宣布，其在研反義寡核苷酸藥物貝匹羅韋生（bepirovirsen）在其主要臨床試驗中取得了具有統計學意義的功能性臨床實驗。這比傳統標準核苷類似物療法約1%的治癒率有了顯著提高。此外，適應症擴展至急性呼吸道病毒感染疾病，正在慢性病原體之外建立強勁的輔助收入來源。製藥公司已成功將用於治療地方性呼吸道感染疾病的口服直接抗病毒藥物商業化，確保即使在疫情危機消退後，市場活動仍將持續。該領域的強勁業績也證明了其財務韌性。輝瑞在 2025 年 11 月發布的題為「輝瑞公佈 2025 年第三季強勁業績」的新聞稿中強調，該公司口服抗病毒藥物 Paxlovid 僅在 2025 年第三季就創造了 12.3 億美元的銷售額，凸顯了急性病毒感染疾病治療的經濟重要性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：直接作用抗病毒藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（NS3/4A 蛋白酶、NS5A 蛋白、NS5B RNA 依賴性 RNA聚合酵素）
    • 適應症（C型肝炎病毒、愛滋病毒感染疾病/愛滋病、流感、預防）
    • 給藥途徑（靜脈注射、口服、皮下注射、外用）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美直接抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲直接抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區直接抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲直接作用抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲直接作用抗病毒藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球直接抗病毒藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Natco Pharma Ltd
  • Vertex Pharmaceuticals Inc
  • Dr Reddy's Laboratories Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Gilead Sciences Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Co

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17474

The Global Direct-acting Antiviral Drug Market is projected to expand significantly, growing from USD 11.91 Billion in 2025 to USD 23.71 Billion by 2031, demonstrating a robust CAGR of 12.16%. Direct-acting antiviral (DAA) drugs are specialized pharmaceutical agents engineered to target specific non-structural proteins within the viral replication cycle, effectively impeding viral multiplication and achieving high cure rates for infections such as Hepatitis C. This market's growth is primarily fueled by the increasing global prevalence of chronic viral diseases and the concerted efforts by international health organizations to meet disease elimination goals, which necessitates the widespread deployment of effective therapeutic solutions. For instance, the American Association for the Study of Liver Diseases estimated that approximately 50 million people worldwide were living with Hepatitis C in 2025, underscoring the substantial demand for these interventions. Despite this significant clinical demand, the market faces a considerable challenge due to the high cost of branded therapies, which restricts patient access, particularly in resource-constrained regions. This economic impediment often compels healthcare systems to impose stringent reimbursement criteria or ration care, thereby hindering the broader adoption of these treatments and limiting the overall market potential in low- and middle-income countries, where the burden of these diseases is frequently highest.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.91 Billion
Market Size 2031USD 23.71 Billion
CAGR 2026-203112.16%
Fastest Growing SegmentNS3/4A Protease
Largest MarketNorth America

Market Driver

The escalating global prevalence of Hepatitis C and HIV infections serves as a primary driving force for the Global Direct-acting Antiviral Drug Market, ensuring a continuous need for therapeutic interventions. As viral transmission rates persist, healthcare systems are increasingly obligated to acquire advanced antiviral regimens to manage the disease burden effectively and prevent the progression to chronic stages. This demand is directly correlated with the volume of new cases requiring immediate medical attention and sustained viral suppression. According to the 'Global HIV & AIDS Statistics - Fact Sheet' published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) in July 2024, an estimated 1.3 million people globally were newly infected with HIV in 2024, indicating a steady influx of patients that stimulates market expansion as manufacturers scale production to meet the needs of this growing population, especially in regions prioritizing effective viral suppression. Further propelling market growth are robust clinical pipelines and ongoing R&D investments, which are leading to the development of long-acting and highly efficacious therapeutics. Pharmaceutical developers are actively pursuing next-generation direct-acting antivirals that offer superior clinical outcomes and reduced dosing frequencies, substantially improving patient adherence. A notable example of this innovation is recent clinical breakthroughs in HIV prevention; Gilead Sciences reported in September 2024 that its investigational twice-yearly injectable lenacapavir reduced HIV infections by 96% in the PURPOSE 2 trial compared to background incidence, demonstrating the transformative potential of new therapeutic classes. This emphasis on enhanced efficacy directly translates into strong commercial performance for key market players, as evidenced by Gilead Sciences' HIV product sales, which increased by 9% to reach $5.1 billion in the third quarter of 2024, reflecting the effective conversion of clinical demand into revenue.

Market Challenge

The substantial cost of branded therapies represents a significant economic barrier that directly impedes the growth of the Global Direct-acting Antiviral Drug Market. In numerous regions, especially low- and middle-income countries where the disease burden is most concentrated, national healthcare budgets are often insufficient to support the premium pricing associated with these patented regimens. This financial pressure compels public health systems to implement strict rationing protocols, frequently restricting drug access to only patients with advanced liver damage while deferring treatment for a larger infected population. Consequently, the market volume is artificially suppressed, hindering the conversion of high clinical prevalence into actual pharmaceutical sales. This affordability gap creates a significant disconnect between the availability of highly effective cures and their widespread adoption. When healthcare infrastructure cannot support broad procurement due to pricing that is prohibitive to local economies, the scalable growth of the market is stifled. Data from the World Hepatitis Alliance in 2024 indicated that only 15 percent of individuals diagnosed with Hepatitis C globally had received necessary treatment, underscoring the profound impact of these access barriers. Such restrictions ensure that a vast majority of the addressable market remains untapped, thereby preventing the industry from realizing its full revenue potential worldwide.

Market Trends

A prominent strategic trend involves the pursuit of functional cures for Hepatitis B, shifting the focus towards finite-duration therapies rather than lifelong viral suppression. This trend is stimulating the development of innovative antisense oligonucleotides engineered to clear viral surface antigens, thereby addressing a substantial unmet need within a therapeutic landscape predominantly characterized by maintenance drugs. Recent clinical advancements validate this trajectory; for instance, GSK announced in January 2026 that its investigational antisense oligonucleotide, bepirovirsen, achieved a statistically significant functional cure rate in pivotal trials, marking a considerable improvement over the approximately 1 percent cure rate historically observed with standard nucleoside analogue regimens. Additionally, the expansion into acute respiratory viral indications is establishing a robust secondary revenue stream, extending beyond chronic pathogens. Pharmaceutical developers are successfully commercializing oral direct-acting antivirals for endemic respiratory infections, ensuring sustained market activity even as the urgency of pandemics subsides. The financial resilience of this segment is demonstrated by strong performance; Pfizer's 'Pfizer Reports Solid Third-Quarter 2025 Results' press release in November 2025 highlighted that its oral antiviral, Paxlovid, generated $1.23 billion in revenue during the third quarter of 2025 alone, confirming the economic significance of therapeutics for acute viral infections.

Key Market Players

  • Natco Pharma Ltd
  • Vertex Pharmaceuticals Inc
  • Dr Reddy's Laboratories Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Gilead Sciences Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Co

Report Scope

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type

  • NS3/4A Protease
  • NS5A Protein
  • NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication

  • Hepatitis C Virus
  • HIV Infection/ AIDS
  • Influenza
  • Prophylaxis

Direct-acting Antiviral Drug Market, By Route

  • Intravenous
  • Oral
  • Subcutaneous
  • Topical

Direct-acting Antiviral Drug Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Direct-acting Antiviral Drug Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

Global Direct-acting Antiviral Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
    • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
    • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
    • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Direct-acting Antiviral Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Route
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Route
        • 6.3.1.2.4. By Distribution Channel
    • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Route
        • 6.3.2.2.4. By Distribution Channel
    • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Route
        • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Route
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Route
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. France Direct-acting Antiviral Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Route
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. United Kingdom Direct-acting Antiviral Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Route
        • 7.3.3.2.4. By Distribution Channel
    • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Route
        • 7.3.4.2.4. By Distribution Channel
    • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Route
        • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Direct-acting Antiviral Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Route
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Route
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. India Direct-acting Antiviral Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Route
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. Japan Direct-acting Antiviral Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Route
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. South Korea Direct-acting Antiviral Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Route
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Australia Direct-acting Antiviral Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Route
        • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Direct-acting Antiviral Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Route
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Route
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. UAE Direct-acting Antiviral Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Route
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. South Africa Direct-acting Antiviral Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Route
        • 9.3.3.2.4. By Distribution Channel

10. South America Direct-acting Antiviral Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indication
    • 10.2.3. By Route
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Route
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Colombia Direct-acting Antiviral Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Route
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Argentina Direct-acting Antiviral Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Route
        • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Direct-acting Antiviral Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Natco Pharma Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Vertex Pharmaceuticals Inc
  • 15.3. Dr Reddy's Laboratories Ltd
  • 15.4. Johnson & Johnson
  • 15.5. Merck & Co Inc
  • 15.6. Gilead Sciences Inc
  • 15.7. AbbVie Inc
  • 15.8. Bristol-Myers Squibb Co

16. Strategic Recommendations

17. About Us & Disclaimer